Removes KITLG (NCBIGene:4254 / SCF-1) from the expected nodes list in the imatinib to asthma test asset.#134
Merged
Conversation
uhbrar
approved these changes
Jul 14, 2026
This file contains hidden or bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment
2 participants
Add this suggestion to a batch that can be applied as a single commit.This suggestion is invalid because no changes were made to the code.Suggestions cannot be applied while the pull request is closed.Suggestions cannot be applied while viewing a subset of changes.Only one suggestion per line can be applied in a batch.Add this suggestion to a batch that can be applied as a single commit.Applying suggestions on deleted lines is not supported.You must change the existing code in this line in order to create a valid suggestion.Outdated suggestions cannot be applied.This suggestion has been applied or marked resolved.Suggestions cannot be applied from pending reviews.Suggestions cannot be applied on multi-line comments.Suggestions cannot be applied while the pull request is queued to merge.Suggestion cannot be applied right now. Please check back later.
In the biological topology, KITLG and imatinib act as converging branches into the KIT receptor. Because our algorithm strictly evaluates and returns direct, linear path traversals between two target entities, the path from imatinib to asthma does not traverse KITLG. Removing this node aligns the test asset with our direct-path output constraints (confirmed via team discussion with Jared Roach).